SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.
- DOI
- 10.1136/jitc-2024-010739
- Published
- 2025 Jun 22
- Container
- Journal for immunotherapy of cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2024-010739,
title = {SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.},
author = {Emens LA and Moussion C and Hwu P and Gulley JL and Ohashi PS and Bifulco CB and Feltquate D},
year = {2025},
journal = {Journal for immunotherapy of cancer},
doi = {10.1136/jitc-2024-010739},
url = {https://doi.org/10.1136/jitc-2024-010739}
}RIS
TY - JOUR TI - SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development. AU - Emens LA AU - Moussion C AU - Hwu P AU - Gulley JL AU - Ohashi PS AU - Bifulco CB AU - Feltquate D PY - 2025 JO - Journal for immunotherapy of cancer DO - 10.1136/jitc-2024-010739 UR - https://doi.org/10.1136/jitc-2024-010739 ER -
APA
LA, E., C, M., P, H., JL, G., PS, O., CB, B., & D, F. (2025). SITC perspective: leveraging patient enrichment biomarkers to accelerate early phase IO drug development.. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2024-010739
Source records
- pubmed · retrieved 2026-09-27T11:24:19.278Z